Scabies Surveillance, Prevention, and Control


Christine K. Cahill, MS, BS, RN, Jon Rosenberg, MD, Steven J. Schweon, RN, MPH, CIC, HEM, Philip W. Smith, MD, and Lindsay E. Nicolle, MD, FRCPC

Scabies is a contagious parasitic disease (infestation) of the skin that can infect residents of long-term care facilities. By the time scabies is suspected, many residents and staff have been exposed, and, until properly treated, continued transmission is predictable. Facility outbreak control policies either do not exist or are outdated, resulting in the administration of ineffective scabicides or scabicides being improperly administered. To prevent outbreaks, facilities should develop a written scabies outbreak control plan; train healthcare workers to recognize, document, and report the condition of residents’ skin at the time of admission, and frequently thereafter; implement barrier precautions for residents with suspicious rashes or symptoms; perform diagnostic tests; and treat cases and their contacts with an effective scabicide. (Annals of Long-Term Care: Clinical Care and Aging 2009;17[4]:31-35) What Is Scabies? Whisper the word scabies in any long-term care facility, and there is immediate panic associated with psychosomatic itching and an image of microscopic bugs crawling on the skin. Scabies is a contagious parasitic disease (infestation) of the skin caused by the human itch mite, Sarcoptes scabiei var hominis. Scabies affects only humans and does not discriminate based on socioeconomic level, gender, ethnicity, age, race, sexual orientation, or personal hygiene habits.1 The life cycle2,3 of the scabies mite begins when one or several pregnant females are transferred from the skin of an infested person to the skin of an uninfested person. Following transfer, the pregnant mite wanders haphazardly around the skin surface before selecting a suitable burrow site. Once a site is selected, the mite(s) secretes a saliva-like substance and uses its four stubby legs to burrow through the outer layer of the host’s skin. A fertile female can lay about three eggs each day. The eggs hatch in 3-4 days, producing larvae that migrate to the surface of the skin, dig another burrow, and feed on intracellular fluids. Over the next 7-10 days, the larvae develop into sexually mature adult mites. This cycle is repeated many times during the 2-month lifespan of the female mite. The male mites have a very short lifespan (1-2 days) that is spent seeking out unmated females. In healthy persons, fewer than 10% of the eggs live long enough to reach adulthood. Most of the eggs are removed from the skin during bathing or other actions such as scratching. Once a female mite leaves the human skin, its life is terminated in about 3-4 days. The severity of the infestation is related to the number of mites residing on the skin and the length of time between the initial infestation and subsequent treatment. If diagnosis and treatment are delayed, the number of mites multiplies daily, resulting in progression of the infestation from a typical or classic form (eg, fewer than 50 mites on the skin)3 to a heavier or atypical infestation. Keratotic or crusted scabies, sometimes referred to as Norwegian scabies, was first described in persons diagnosed with leprosy in Norway.4 This severe form of scabies is generally characterized by thick, crusty skin lesions. Embedded within these crusts are thousands to millions of live mites.5 There are several physiological and immunological conditions—including renal failure, insulin-dependent diabetes, severe mental retardation, malnutrition, acquired immunodeficiency syndrome (AIDS), T-cell leukemia,6 and the administration of topical and systemic corticosteroids1,3—that can hasten the progression of the infestation. Recognizing Scabies Healthy persons with no history of previous infestation will have no signs or symptoms immediately following an exposure and during the initial 3-6–week incubation period. Following the incubation period, the infested person will complain of pruritus, which intensifies at bedtime. Pruritus is a cell-mediated hypersensitivity (allergic) response to the mites, eggs, and feces embedded in the skin.3 In previously infested persons, pruritus may be noticeable as soon as 48 hours following exposure. The areas of the skin most affected by the mites include the webs between the fingers, buttocks, genitalia, under the folds of women’s breasts, flexor surfaces of the wrists and elbows, and axillae.2 In bedridden residents, lesions may be more prominent on the back, buttocks, and the backs of the legs.7 The affected skin areas are generally inflamed with nonspecific raised bumps and small, almost microscopic, short, wavy, slightly elevated lines or burrows.5 If the skin is not excoriated due to scratching, burrows with associated vesicles can sometimes be visualized with a magnifying lens. To review the many visual presentations of both typical and atypical scabies, the reader is referred to The rash may mimic other dermatological conditions, including eczema, drug reaction, impetigo, folliculitis, dermatitis herpetiformis, pyoderma, tinea, pityriasis, psoriasis, syphilis, mycosis fungoides, lupus, acute urticaria, insect bites, and contact dermatitis.2,8 The excoriated skin lesions may become secondarily infected with Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus) or Group A streptococci.4,8 Transmission The scabies mite is transmitted from person to person by direct contact with the skin of the infested person. Atypical or crusted scabies may also be transmitted by wearing an infested person’s clothing (fomites) such as sweaters, coats, or scarves. Activities such as performing physical assessments and bathing are conducive to transmission because physical contact is often prolonged. Transmission may also occur between residents during social or recreational activities. Inanimate objects such as bed linens, personal clothes, and fabric-covered chairs or sofas will play little, if any, role in transmission if the infestation is typical.3 However, residents with atypical or crusted scabies can shed an estimated 7000 live mites into the environment every 2 days, increasing the risk of transmission from an environmental source.5 Scabies Outbreak Control Plan Facilities should develop and periodically revise a written outbreak control plan9,10 (Table I). Healthcare workers should be trained to perform a skin assessment on the day of admission and periodically thereafter, and to immediately document and report verbal symptoms and visual changes in the condition of the skin. Until a diagnosis of scabies is ruled out, appropriate barriers including gowns and gloves to prevent transmission should be implemented.11 The facility medical director should be given authority to notify residents’ attending physicians, perform diagnostic tests, and order appropriate treatment. The infection control practitioner should be responsible for identifying symptomatic cases and their contacts, implementing and discontinuing barrier precautions, educating staff, and ensuring that visitors and volunteers are notified and treated, if necessary.9 Outbreak Definition Local health department jurisdictions may have slightly different definitions of a scabies outbreak. Since scabies is not a normally occurring disease in any facility, an outbreak might be defined as one or more confirmed or suspected cases occurring within a defined period of time and within a defined geographical location (nursing unit, physical therapy department, or, in some cases, the entire facility). An example of a case definition might be one resident with a positive skin scraping and one or more symptomatic residents or healthcare workers.9 Diagnostic Procedures The diagnosis of typical scabies can be difficult, especially in elderly persons with preexisting, chronic dermatological conditions. Skin scrapings (Table II) when performed properly will almost always be positive in residents with atypical or crusted scabies.2,3 However, recently exposed, symptomatic residents are more likely to have typical scabies, and skin scrapings—even when repeated several times at different sites—may be negative. The absence of mites, eggs, or fecal pellets on microscopic examination does not exclude a diagnosis of scabies.7 If skin scrapings are negative, the burrow ink test3,8 may provide clues to aid in the diagnosis (Table II). This is an insensitive method of diagnosing scabies and may only be useful for a few days following the onset of symptoms. If the scrapings are negative and the ink test is inconclusive, it may be necessary to proceed with treatment based on symptoms rather than a verified diagnosis. Physicians, including those who specialize in dermatology, generally have limited practical experience in diagnosing scabies7; however, in difficult cases, a dermatology consult may be prudent. Some of the more advanced diagnostic techniques used in limited clinical situations include skin biopsy and videodermatoscopy.4 Controlling the Outbreak The Centers for Disease Control and Prevention (CDC) currently recommends contact precautions until 24 hours after initiation of effective therapy.11 However, current treatment recommendations for atypical or crusted scabies may require several treatments, and severely infested residents may not be rendered noncontagious for several weeks. Therefore, residents with crusted scabies should be placed on contact precautions in a single-bed room until at least three consecutive skin scrapings are negative and symptoms have resolved.5 Precautions for recently exposed symptomatic residents and their asymptomatic contacts should include gowns and gloves during the treatment period. Personal clothes, wheelchair pads, pillows, and blankets can be either washed, sealed in a plastic bag for 5-7 days, placed in a hot dryer, or dry-cleaned. Residents should put on clean clothes at the end of each treatment. Environmental surfaces including wheelchairs, walkers, bed frames, tables, chairs, blood pressure cuffs, walking belts, and other equipment and surfaces should be cleaned and disinfected with an Environmental Protection Agency (EPA)–registered product approved for use in healthcare facilities. Cloth or fabric-covered furniture may need to be sequestered for 5-7 days. Topical creams, ointments, and lotions should be discarded.7 Carpets should be vacuumed, and the bag should be immediately discarded. Hands should be washed after contact with each resident, with their environment, and after removing gloves. Treatment The most common source of a scabies outbreak is the resident admitted with undiagnosed, untreated, or improperly treated atypical or crusted scabies. If the infestation is not recognized promptly, within 3-6 weeks new complaints of symptoms (rash and/or itching) are likely to occur sporadically throughout the facility in residents, healthcare workers, and staff who provide indirect care, such as housekeepers, laundry personnel, administrative staff, visitors, and volunteers. Because an untreated contact may be infested and transmit scabies prior to becoming symptomatic, continuous transmission can occur over a prolonged period of time. Ridding scabies from the facility then becomes a long, protracted, and costly ordeal. Controlling transmission9,10 often involves a choice between treating only symptomatic residents and their identified contacts (contact prophylaxis), or treating all possible contacts (mass prophylaxis). There is limited published information on which to base any recommendation. Mass prophylaxis can be almost entirely avoided if there is a high index of suspicion and appropriate steps, including an assessment of the resident’s skin and symptoms, are implemented at the time of admission (Table III). For mass prophylaxis to be cost-effective, the decision to choose it should be made as soon as possible after an outbreak is suspected. Key factors favoring mass prophylaxis include the length of time an undiagnosed, nonisolated case has been in the facility, the mobility of the infested resident, and the number of symptomatic cases occurring in other residents and staff within a 2-6–week period (Table IV). Until recently, the treatment for scabies was 1% gamma-hexachlorocyclohexane. However, the mites have become increasingly resistant to this product, and it is no longer recommended. Additionally, neurotoxicity has been reported following a single application.12,13 Permethrin 5% Cream For recent exposures and residents considered to have typical or classic scabies, permethrin cream, when applied as directed, is approximately 90% effective after one application. However, a second application 7-10 days after the first may be necessary to ensure complete eradication.14 Permethrin has a low rate of side effects that may include burning, stinging, or itching immediately following the application.12 Animal studies have shown no adverse effects to reproductive function or to the fetus; however, studies have not been conducted on pregnant women. Therefore, permethrin should be used during pregnancy only if there is a clear indication for treatment. Breastfeeding should be discouraged during the treatment period. Permethrin is safe for children two months of age or older.13 If permethrin is selected, all symptomatic residents and their close contacts including staff should be treated within the same 24-48–hour period. Healthcare workers should apply permethrin to themselves and household contacts at the end of the work shift, shower after 8-12 hours, and return to work as scheduled. The question of treating asymptomatic staff who have had no or rare contact with a symptomatic case is challenging. However, approval for one application of a topical scabicide should be granted, if requested.9 Healthcare workers should be trained in the proper application of the topical scabicide. Permethrin should be massaged into the entire area of the skin from the hairline to the feet, including the palms of the hands and soles of the feet and under the fingernails and toenails.4 In rare instances, the infested scalp may need to be treated.2 Topical scabicides should be reapplied frequently throughout the 8-12–hour treatment period to areas of the skin exposed to moisture, including urinary and fecal incontinence, and after hand hygiene. After the treatment period, residents should be bathed or showered to remove the scabicide, and bed linens should be changed.2,8 If treatment with permethrin has been effective, the intensity of pruritus and rash should gradually resolve over a 7-14–day period. If signs and symptoms persist or intensify, or if new lesions are identified, treatment failure should be considered.8 Dermatologists recommend applying 1% hydrocortisone cream or triamcinolone cream (0.1-0.025%) to the most intense areas of pruritus. Steroid creams should not be applied until after the scabicide has been removed. Antihistamines may also be effective in relieving some of the symptoms.2 Ivermectin Ivermectin is an antiparasitic agent that has been used extensively to treat river blindness (onchocerciasis) in Africa. The drug is not approved by the U.S. Food and Drug Administration in the treatment of scabies; however, there is increasing literature to support its use.13 Currently, for typical scabies, the CDC recommends either permethrin cream or ivermectin 200 ucg/kg initially. A second dose of ivermectin 2 weeks after the initial dose increases the cure rate to 95%.14,15 Limited information on the half-life of ivermectin in the blood suggests that the duration of protection from re-infestation after administration is short (eg, less than a week).15 Ivermectin, either alone or in combination with a topical scabicide such as permethrin, is the treatment of choice for crusted scabies in immunocompromised patients.12 Ivermectin adverse reactions may include nausea, rash, dizziness, itching, abdominal pain, fever, and increased heart rate.12 These symptoms may be due to the release of large numbers of antigens following the death of the scabies mite, rather than a reaction to the drug itself. Ivermectin is not recommended for use in children less than 33 pounds or in pregnant or nursing women.13 Post-Treatment Assessment There are a number of reasons for the continued propagation of new cases in healthcare facilities. The most common reason is delayed recognition of the index case.1 Other reasons include: (1) continued contact with untreated or unsuccessfully treated residents and healthcare workers; (2) failure of residents who have immunosuppressive diseases such as AIDS to respond appropriately to the scabicide5; (3) continued use of topical and oral steroids during the treatment period(s)1,3; and (4) failure to kill the scabies mite in clothing, upholstered furniture, or carpeting.2,5 If scabies control measures have been successful, an endpoint for the outbreak should be evident within 6-12 weeks (2 incubation periods) after the last case has been identified.9 Summary Outbreaks of scabies have been reported in acute care hospitals and long-term care facilities, and have involved both patients and staff. In the studies reviewed, the single most important cause of the outbreaks was failure to observe and document the condition of the skin at the time of admission and take immediate and appropriate action to diagnose, treat, and prevent transmission. To prevent outbreaks, facilities should develop a written scabies outbreak control plan; train healthcare workers to recognize, document, and report the condition of residents’ skin at the time of admission, and frequently thereafter; implement barrier precautions for residents with suspicious rashes or symptoms; perform diagnostic tests; and treat cases and their contacts with an effective scabicide. The authors report no relevant financial relationships. Ms. Cahill is an Infection Prevention and Control Consultant, La Quinta, CA; Dr. Rosenberg is in the Division of Communicable Disease Control, Infectious Diseases Branch, Healthcare Associated Infections, California Department of Public Health, Richmond; Mr. Schweon practices in Saylorsburg, PA; Dr. Smith is Chief, Section of Infectious Diseases, Nebraska Medical Center, Omaha; and Dr. Nicolle is Professor, Internal Medicine and Medical Microbiology, University of Manitoba Health Sciences Centre, Winnipeg, Manitoba, Canada.